Clinical Research & Reference Standard Compendium
Extended GH / IGF - Scientific Literature
I. Abstract & Overview
Extended GH / IGF supplies CJC-1295 with DAC (5 mg), Ipamorelin (5 mg) and IGF-1 LR3 (1 mg) as three separately labelled lyophilized vials spanning hormone release through to downstream receptor tyrosine kinase signaling. It is the only panel in this range combining solid-phase synthetic peptides with a recombinant expressed protein, which is why the three vials carry two different release protocols. The IGF-1 LR3 fill is set at 1 mg to match assay consumption rather than matched to the peptides by milligram. Supplied for Research Use Only.
II. Chemical Specifications
| Molecular Formula | Blend — no single formula applies; CJC-1295 with DAC C165H269N47O46, Ipamorelin C38H49N9O5, IGF-1 LR3 not indexed in PubChem — verify with manufacturer COA |
|---|---|
| Molar Mass | CJC-1295 with DAC 3647.2 g/mol; Ipamorelin 711.9 g/mol; IGF-1 LR3 approximately 9100 g/mol as an 83-residue protein — verify with manufacturer COA |
| CAS Registry Number | Blend |
| Amino Acid Sequence | CJC-1295 with DAC, GHRH(1-29) analog with four substitutions plus an albumin-binding group; Ipamorelin Aib-His-D-2-Nal-D-Phe-Lys-NH2; IGF-1 LR3, 83-residue recombinant protein |
III. Mechanism & Cellular Signaling Pathways
CJC-1295 with DAC is a GHRH(1-29) analog bearing four amino acid substitutions that resist enzymatic degradation plus an albumin-binding group that forms a covalent conjugate in circulation; work by Jetté and colleagues established that such albumin bioconjugates still activate the pituitary GHRH receptor. Ipamorelin acts selectively at GHS-R1a. IGF-1 LR3 operates one level down, binding the IGF-1 receptor directly; its reduced affinity for IGF binding proteins, engineered through an amino-terminal extension and a position-three substitution, is the property Tomas and colleagues characterised as producing more prolonged action than native IGF-1.
IV. Primary Research Directions
- The only panel in this range spanning solid-phase synthetic peptides and a recombinant expressed protein, with two distinct release protocols documented per manufacturing route
- IGF-1 LR3 released on SDS-PAGE and disulfide folding confirmation rather than a peptide purity assay that would confirm the wrong properties for a folded protein
- Upstream secretagogue pair plus a downstream effector that bypasses the pituitary, enabling an experiment to localise where along the axis an observation originates
- CJC-1295 supplied unambiguously as the with-DAC form under CAS 446262-90-4, correcting the widely circulated registry number that actually maps to the no-DAC molecule
- Written statement that no independently confirmable molecular formula exists for IGF-1 LR3, with observed mass reported instead of a calculated figure
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). 'Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.' Endocrinology, 146(7), 3052-3058. DOI: 10.1210/en.2004-1286 | PMID: 15817669
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
- Tomas, F. M., Walton, P. E., Dunshea, F. R., et al. (1997). 'IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.' Journal of Endocrinology, 155(2), 377-386. DOI: 10.1677/joe.0.1550377 | PMID: 9415072
Extended GH / IGF
Abstract & Overview
Extended GH / IGF supplies CJC-1295 with DAC (5 mg), Ipamorelin (5 mg) and IGF-1 LR3 (1 mg) as three separately labelled lyophilized vials spanning hormone release through to downstream receptor tyrosine kinase signaling. It is the only panel in this range combining solid-phase synthetic peptides with a recombinant expressed protein, which is why the three vials carry two different release protocols. The IGF-1 LR3 fill is set at 1 mg to match assay consumption rather than matched to the peptides by milligram. Supplied for Research Use Only.
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Extended GH / IGF) | 8.90 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 8.90 minutes represents the active compound (Extended GH / IGF). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
CJC-1295 with DAC is a GHRH(1-29) analog bearing four amino acid substitutions that resist enzymatic degradation plus an albumin-binding group that forms a covalent conjugate in circulation; work by Jetté and colleagues established that such albumin bioconjugates still activate the pituitary GHRH receptor. Ipamorelin acts selectively at GHS-R1a. IGF-1 LR3 operates one level down, binding the IGF-1 receptor directly; its reduced affinity for IGF binding proteins, engineered through an amino-terminal extension and a position-three substitution, is the property Tomas and colleagues characterised as producing more prolonged action than native IGF-1.
Primary Research Directions
The only panel in this range spanning solid-phase synthetic peptides and a recombinant expressed protein, with two distinct release protocols documented per manufacturing route
IGF-1 LR3 released on SDS-PAGE and disulfide folding confirmation rather than a peptide purity assay that would confirm the wrong properties for a folded protein
Upstream secretagogue pair plus a downstream effector that bypasses the pituitary, enabling an experiment to localise where along the axis an observation originates
CJC-1295 supplied unambiguously as the with-DAC form under CAS 446262-90-4, correcting the widely circulated registry number that actually maps to the no-DAC molecule
Written statement that no independently confirmable molecular formula exists for IGF-1 LR3, with observed mass reported instead of a calculated figure
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). 'Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats.' Endocrinology, 146(7), 3052-3058. DOI: 10.1210/en.2004-1286 | PMID: 15817669
Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
Tomas, F. M., Walton, P. E., Dunshea, F. R., et al. (1997). 'IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.' Journal of Endocrinology, 155(2), 377-386. DOI: 10.1677/joe.0.1550377 | PMID: 9415072
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
